PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Prices as of the 2026-10-02 close
Cell Bio Human Tech posted record annual results in 2025 on improved high-margin product mix in its mask-pack fiber material business, and is now expanding into cosmetics OEM/ODM, hydrogel, and the Sinsedae acquisition.
2025 consolidated revenue reached KRW 51.0bn (up 79.6% YoY), operating profit KRW 9.3bn (up 132.5%), and owner net profit KRW 8.7bn (up 100.0%), marking the company's largest annual results since founding.
Improved product mix from expanded sales of the high-margin PT Cell mask-sheet material line drove the rise in operating margin.
The company became the controlling shareholder of household/beauty products maker Sinsedae in December 2025, and its Hwaseong Plant 1 obtained MFDS CGMP certification in August 2026.
Revenue and profit softened in Q1 2026 versus the prior quarter, then recovered with Q2 2026 revenue of KRW 19.4bn, the company's largest quarterly revenue on record.
Amid favorable industry conditions including strong global mask-pack export growth and expanding hydrogel product demand, the company is expanding production capacity in Vietnam.
Cell Bio Human Tech began as a developer and manufacturer of mask-pack sheet materials made by modifying the molecular structure of cellulose fibers, with core products including PT Cell (bamboo-derived), Semi Gel (high-absorption Lyocell), S Cell (rayon), and NC Cell (transparent Lyocell) eco-friendly mask-sheet materials.
Based on cumulative nine-month 2025 figures, revenue mix was reported as roughly 43.4% PT Cell line, 20.3% Semi Gel line, 14.7% cosmetics OEM/hydrocolloid/brand business, and 21.6% other, according to a KB Securities report dated February 2026.
The company directly produces nonwoven fabric through its Da Nang, Vietnam subsidiary to cut costs and manage quality, and expanded material production equipment at the Da Nang plant in March 2026.
Since July 2025, it has operated a CGMP-compliant cosmetics manufacturing facility, establishing a foothold in cosmetics OEM/ODM, and around the same time converted its hydrogel business to in-house manufacturing.
Its Hwaseong Plant 1 and 2 house manufacturing infrastructure spanning hydrogel mask packs, toner pads, and hydrocolloid acne patches, with Hwaseong Plant 1 obtaining MFDS CGMP certification in August 2026.
In December 2025, the company acquired a stake in Sinsedae, a maker of cotton pads and other products supplied to domestic cosmetics firms, H&B stores, hypermarkets, and e-commerce channels, becoming its controlling shareholder to pursue manufacturing expansion and customer diversification.
A core competitive strength cited is reducing domestic reliance on mask-pack fiber material imports previously sourced from Japan and China, and the company is now transitioning from a materials supplier toward an integrated cosmetics company spanning finished products and brands.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩14B | ₩3B | 21.6% |
| 2025Q3 | ₩14.5B | ₩3.6B | 24.9% |
| 2025Q4 | ₩14.3B | ₩1.2B | 8.5% |
| 2026Q1 | ₩12.7B | ₩1.5B | 11.4% |
| 2026Q2 | ₩19.4B | ₩3.5B | 18.0% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩27.5B | ₩3.5B | ₩2.9B | 12.8% | 9.0% | 43.0% |
| 2023 | ₩27.3B | ₩3.1B | -₩1.9B | 11.5% | −4.2% | 19.4% |
| 2024 | ₩28.4B | ₩4B | ₩4.4B | 14.2% | 9.4% | 14.0% |
| 2025 | ₩51.1B | ₩9.3B | ₩8.7B | 18.2% | 15.4% | 49.9% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
Consolidated revenue in 2025 was KRW 51.07bn, sharply up from KRW 28.42bn in 2024, while operating profit rose to KRW 9.32bn (18.2% operating margin) from KRW 4.04bn (14.2%) in 2024, showing margin improvement. Owner net profit reached KRW 8.72bn, roughly double the KRW 4.38bn recorded in 2024.
The company posted an owner net loss of KRW -1.86bn in 2023, following a KRW 2.89bn profit in 2022, before returning to profit growth in 2024-2025.
By quarter, revenue was KRW 13.99bn with operating profit of KRW 3.02bn and owner net profit of KRW 1.62bn in Q2 2025, improving to revenue of KRW 14.54bn, operating profit of KRW 3.61bn, and owner net profit of KRW 3.52bn in Q3 2025.
In Q4 2025, revenue held near KRW 14.25bn but operating profit fell to KRW 1.22bn while owner net profit was KRW 2.20bn.
Q1 2026 saw revenue of KRW 12.75bn and operating profit of KRW 1.46bn, both lower than the prior quarter, with owner net profit of KRW 1.91bn; the company attributed this to temporary factors affecting the quarter.
This was followed by a clear rebound in Q2 2026, with revenue of KRW 19.36bn, operating profit recovering to KRW 3.49bn, and owner net profit of KRW 2.93bn, which the company described as its largest quarterly revenue on record.
Summed across the most recent four quarters from Q3 2025 through Q2 2026, owner net profit totaled KRW 10.57bn, already exceeding the full-year 2025 owner net profit of KRW 8.72bn.
That said, the margin swings seen in Q4 2025 and Q1 2026 illustrate that product mix and temporary factors can create noticeable quarter-to-quarter variability.
Korean mask packs are shifting in character from a tourist shopping item toward a leading global export category, with analysis noting mask packs were, as of 2024 data, among Korea's world No.1 export-share products for the first time.
Mask-pack exports rose 86% year-on-year in March 2026, and Korea Customs Service data showed mask-pack exports for the January-July 2026 period up 25.8% versus the same period a year earlier, indicating continued growth momentum.
Hydrogel mask packs in particular are cited as a fast-growing category in North America, driven by strong adhesion and cooling sensation, with one market research firm projecting the global hydrogel face-mask market to grow from $116 million in 2023 to $240 million by 2030 at an 11.0% CAGR.
However, industry observers also note that competition has intensified rapidly as major brands such as Medi-Heal, Torriden, and Anua expanded their hydrogel product lines after the category was popularized starting with Biodance, according to a Meritz Securities analyst cited in April 2026.
The overall global face mask market is projected to grow from roughly $7.95 billion in 2026 to $9.08 billion by 2031 at an 8.76% CAGR, with Asia-Pacific accounting for a substantial share of global sales.
Cell Bio Human Tech, in transitioning from a materials supplier toward finished products and brands, is positioned with exposure across multiple stages of this growth cycle.
The company has outlined a 2026 growth strategy centered on expanding material production capacity, ramping up the hydrogel business, and broadening its customer network through the Sinsedae acquisition.
The company stated that its Da Nang, Vietnam plant completed an expansion of mask-pack material production equipment in March 2026 and was ready for operation.
Hwaseong Plant 1 obtained MFDS CGMP certification in August 2026, which the company said would strengthen product credibility with domestic and overseas clients and accelerate its push into global cosmetics markets.
Hwaseong Plant 2 was newly secured in May 2026 to house relocated hydrocolloid production equipment as a dedicated manufacturing space, with Hwaseong Plant 1 now focused on hydrogel mask packs and basic cosmetics manufacturing.
The company is also pursuing collaboration with global cosmetics firms and material product development with Japanese and Chinese clients, though it has cautioned that such collaborations remain at an early stage and concrete results should be viewed carefully.
Through the Sinsedae acquisition, the company expects to diversify its customer base via cotton pads and other household/beauty product manufacturing.
The company said in an August 2026 press release that it expects stable earnings growth to continue into the third quarter, supported by steady growth in its existing fiber-material business and expansion of cosmetics OEM/ODM.
Cell Bio Human Tech has moved from a net loss in 2023 to a profit-recovery phase in 2024-2025, and its trailing four-quarter performance from Q3 2025 through Q2 2026 has already exceeded full-year 2025 results, suggesting a period where changing earnings estimates could feed into how the market values the stock.
Without a recently disclosed per-share dividend, it makes more sense to focus on earnings growth and balance-sheet changes rather than dividend appeal.
The debt ratio rose from 14.0% in 2024 to 49.9% in 2025, which can be interpreted as reflecting a change in capital structure tied to business expansion, including the Sinsedae acquisition.
The stock's valuation relative to net assets or earnings appears to be in a re-rating process typical of a turnaround phase, and which direction this relationship moves will likely hinge on confirming quarterly results going forward.
As a small-cap stock, trading volume and liquidity can be limited, which may also make valuation metrics comparatively more volatile.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
An increasing share of revenue from the high-margin PT Cell product line has driven product-mix improvement that lifted the operating margin. This is supported by the operating margin rising from 14.2% in 2024 to 18.2% in 2025. Cost savings from local production in Vietnam are also understood to be contributing to margin improvement.
Since July 2025, the company has operated a CGMP-standard manufacturing facility, expanding into finished cosmetics products, and in August 2026 its Hwaseong Plant 1 obtained MFDS CGMP certification, formally recognizing its quality credibility.
The hydrogel business has also shifted to in-house manufacturing rather than outsourcing, being cultivated as a new growth driver. The Sinsedae acquisition further diversifies the customer network into household/beauty product manufacturing such as cotton pads.
Korean mask-pack exports rose 86% year-on-year in March 2026 and 25.8% cumulatively for the January-July 2026 period, showing a structural expansion in demand. Hydrogel mask packs are cited as a rapidly growing category in North America and elsewhere.
This industry backdrop provides a favorable external environment for a company expanding from materials into finished products.
Q4 2025 operating profit fell sharply to KRW 1.22bn from KRW 3.61bn in Q3, and Q1 2026 revenue and operating profit were also lower than the prior quarter. While the company attributed this to temporary factors, it suggests earnings variability tied to quarterly product mix and volume shifts could recur.
The hydrogel mask-pack market is assessed as facing rapidly intensifying competition, as major brands including Medi-Heal, Torriden, and Anua have expanded product lines following the category's expansion led by Biodance.
Brand rankings on channels such as China's Tmall have also shifted quickly within a single year, exposing the company, as a material and manufacturing partner, to changes in its client brands' market positions.
With the Sinsedae acquisition and Hwaseong Plant 1/2 capacity expansion proceeding simultaneously, the burden of business integration and capital allocation could increase. The debt ratio rising from 14.0% in 2024 to 49.9% in 2025 reflects this balance-sheet change during the expansion phase.
As a small-cap company, any shortfall in new business performance relative to expectations could have a comparatively larger impact on results.
The cosmetics OEM/ODM and hydrogel businesses remain at an early stage, and the company itself has said it is cautiously monitoring concrete results from related collaborations.
Given how quickly brand rankings shift in the mask-pack and hydrogel markets, changes in the standing of key client brands could affect results.
With a high share of direct production through its Da Nang, Vietnam subsidiary, local raw material supply or exchange rate fluctuations could affect costs and margins. Given the export-oriented business structure, the company is also exposed to changes in tariffs and trade conditions.
Following the Sinsedae acquisition, there could be burdens in integrating customer networks and organizational management, and the debt ratio rising to 49.9% in 2025 from the prior year reflects the financial burden of the expansion phase. If further capex or acquisitions follow, the balance-sheet structure could continue to change.
Q3 2026 earnings are expected to be disclosed around this time, providing a checkpoint on whether the revenue recovery seen in Q2 2026 continues and whether operating margin remains stable.
It will be worth confirming progress on hydrogel/hydrocolloid capacity expansion at Hwaseong Plants 1 and 2, and any new customer orders following the CGMP certification.
This marks the filing of the 2026 annual business report, when the revenue mix shift from the Sinsedae acquisition and cosmetics OEM/ODM business, along with confirmed full-year results, can be verified.
Tracking mask-pack export trends provides an ongoing way to monitor whether downstream demand growth persists.
Cell Bio Human Tech achieved record annual results in 2025 by simultaneously pursuing higher-margin mask-pack fiber materials and expanding into cosmetics OEM/ODM and hydrogel businesses, and continues a profit-recovery trend into 2026 amid quarter-to-quarter variability.
Diversification moves such as the Sinsedae acquisition and CGMP certification remain at an early stage, and the company itself has taken a cautious stance on confirming concrete results.
While a favorable industry backdrop of strong K-beauty and mask-pack export growth provides support, segments such as hydrogel are seeing rapidly intensifying competition, exposing the company to shifts in its client brands' market standing.
The debt ratio rising to 49.9% in 2025 is an indicator of the balance-sheet changes accompanying this expansion phase, warranting continued observation if further investment and acquisitions follow.
Upcoming quarterly results and progress on new facilities and certifications will likely serve as important checkpoints for gauging the tangible outcome of the business transition.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.